These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35064805)

  • 1. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
    Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
    Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
    Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
    Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation between subcentimeter carcinomas and benign lesions using kinetic parameters derived from ultrafast dynamic contrast-enhanced breast MRI.
    Onishi N; Sadinski M; Gibbs P; Gallagher KM; Hughes MC; Ko ES; Dashevsky BZ; Shanbhag DD; Fung MM; Hunt TM; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Eur Radiol; 2020 Feb; 30(2):756-766. PubMed ID: 31468162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-to-enhancement at ultrafast breast DCE-MRI: potential imaging biomarker of tumour aggressiveness.
    Shin SU; Cho N; Kim SY; Lee SH; Chang JM; Moon WK
    Eur Radiol; 2020 Jul; 30(7):4058-4068. PubMed ID: 32144456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.
    Onishi N; Sadinski M; Hughes MC; Ko ES; Gibbs P; Gallagher KM; Fung MM; Hunt TJ; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Breast Cancer Res; 2020 May; 22(1):58. PubMed ID: 32466799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
    Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
    Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density.
    Mori N; Abe H; Mugikura S; Takasawa C; Sato S; Miyashita M; Mori Y; Pineda FD; Karczmar GS; Tamura H; Takahashi S; Takase K
    Acad Radiol; 2019 Jul; 26(7):e141-e149. PubMed ID: 30269956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy.
    Tsukada H; Tsukada J; Schrading S; Strobel K; Okamoto T; Kuhl CK
    Magn Reson Imaging; 2019 Oct; 62():242-248. PubMed ID: 31352016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
    Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
    J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The additional utility of ultrafast MRI on conventional DCE-MRI in evaluating preoperative MRI of breast cancer patients.
    Lee SJ; Ko KH; Jung HK; Koh JE; Park AY
    Eur J Radiol; 2020 Mar; 124():108841. PubMed ID: 31981877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Lesion Conspicuity and Size Assessment according to Background Parenchymal Enhancement.
    Kim SY; Cho N; Choi Y; Shin SU; Kim ES; Lee SH; Chang JM; Moon WK
    Korean J Radiol; 2020 May; 21(5):561-571. PubMed ID: 32323501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
    Han X; Yang H; Jin S; Sun Y; Zhang H; Shan M; Cheng W
    Cancer Med; 2023 Jan; 12(2):1389-1398. PubMed ID: 35822639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer.
    Kato E; Mori N; Mugikura S; Sato S; Ishida T; Takase K
    Jpn J Radiol; 2021 Aug; 39(8):791-801. PubMed ID: 33743147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
    Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
    Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmass Enhancement Breast Lesions: Diagnostic Performance of Kinetic Assessment on Ultrafast and Standard Dynamic Contrast-Enhanced MRI in Comparison With Morphologic Evaluation.
    Mori N; Sheth D; Abe H
    AJR Am J Roentgenol; 2020 Aug; 215(2):511-518. PubMed ID: 32452698
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
    Abdelhafez AH; Musall BC; Adrada BE; Hess K; Son JB; Hwang KP; Candelaria RP; Santiago L; Whitman GJ; Le-Petross HT; Moseley TW; Arribas E; Lane DL; Scoggins ME; Leung JWT; Mahmoud HS; White JB; Ravenberg EE; Litton JK; Valero V; Wei P; Thompson AM; Moulder SL; Pagel MD; Ma J; Yang WT; Rauch GM
    Breast Cancer Res Treat; 2021 Jan; 185(1):1-12. PubMed ID: 32920733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative DCE-MRI for prediction of pathological complete response following neoadjuvant treatment for locally advanced breast cancer: the impact of breast cancer subtypes on the diagnostic accuracy.
    Drisis S; Metens T; Ignatiadis M; Stathopoulos K; Chao SL; Lemort M
    Eur Radiol; 2016 May; 26(5):1474-84. PubMed ID: 26310583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.